Department of Pathology

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Neoplasms 77%
3. Cell Biology 49%
4. Prostate-Specific Antigen 45%
5. Finland 43%
6. Early Detection of Cancer 36%
7. Glioma 34%
8. Survival 32%
9. Fine Needle Biopsy 30%
10. Ion Mobility Spectrometry 27%
11. Salivary Glands 27%
12. Pathology 24%
13. Esophageal Mucosa 24%
14. Biopsy 23%
15. Thyroid Neoplasms 23%
16. Distal Myopathies 23%
17. Thyroid Gland 23%
18. Fundoplication 21%
19. Spectrum Analysis 21%
20. Central Nervous System Neoplasms 21%
21. Glioblastoma 21%
22. Mortality 20%
23. Adenocarcinoma 19%
24. Confidence Intervals 19%
25. Incidence 19%
26. Prostate 19%
27. Astrocytoma 19%
28. Squamous Cell Carcinoma 18%
29. Uterine Cervical Neoplasms 18%
30. Papillary Thyroid Cancer 18%
31. Gastroesophageal Reflux 17%
32. B-Lymphocytes 17%
33. Tongue 16%
34. Renal Cell Carcinoma 16%
35. Insulin-Like Growth Factor Binding Protein 2 16%
36. Diazoxide 15%
37. Autopsy 15%
38. Muscles 14%
39. Hashimoto Disease 14%
40. Immunohistochemistry 14%
41. Distal 3 Myopathy 14%
42. Population 14%
43. Papillomaviridae 14%
44. Papillary Carcinoma 14%
45. Adenocarcinoma in Situ 13%
46. Recurrence 13%
47. Papanicolaou Test 13%
48. Paraffin 13%
49. Hodgkin Disease 13%
50. Esophagus 12%
51. Squamous Cell Carcinoma of Head and Neck 12%
52. B-Cell Lymphoma 12%
53. Pediatrics 12%
54. Genes 12%
55. Androgen Receptors 12%
56. Pandemics 12%
57. Blood Vessels 12%
58. RNA Sequence Analysis 12%
59. varespladib methyl 12%
60. Proteins 12%
61. Atherosclerotic Plaques 12%
62. muraglitazar 11%
63. Esophagogastric Junction 11%
64. Precursor Cell Lymphoblastic Leukemia-Lymphoma 11%
65. Salivary Gland Neoplasms 11%
66. Coronary Artery Bypass 11%
67. Chromatin 10%
68. Tumor-Infiltrating Lymphocytes 10%
69. Biomarkers 10%
70. Mutation 10%
71. Meta-Analysis 10%
72. medicagenic acid-3-O-glucopyranoside 10%
73. Phenomics 9%
74. Carcinoma 9%
75. Fibroblast Growth Factor Receptors 9%
76. Nefopam 9%
77. human PRMT2 protein 9%
78. Tongue Neoplasms 9%
79. Staining and Labeling 9%
80. Oligodendroglioma 9%
81. Netrin Receptors 9%
82. Neoplasm Grading 9%
83. Observer Variation 9%
84. Familial Prostate cancer 9%
85. Tumor Biomarkers 9%
86. Neoplasm Metastasis 9%
87. Heterogeneous Nuclear Ribonucleoprotein A1 9%
88. Breast Neoplasms 9%
89. Ependymoma 9%
90. Lymphocytes 9%
91. Molecular Pathology 9%
92. Minichromosome Maintenance Proteins 9%
93. Nemaline Myopathies 9%
94. Autonomic Pathways 9%
95. 5-alpha Reductase Inhibitors 9%
96. fascin 9%
97. Coronavirus 9%
98. Netrin-1 9%
99. Needle Biopsy 8%
100. Receptor, Fibroblast Growth Factor, Type 3 8%